Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

October 31, 1999

Study Completion Date

January 31, 2002

Conditions
HIV InfectionsChlamydia TrachomatisNeisseria GonorrhoeaeTrichomonas VaginitisSyphilis
Interventions
DRUG

Carraguard (PC-515)

Trial Locations (2)

7925

University of Cape Town, Department of Community Health, Cape Town

0204

Medical University of Southern Africa, Soshanguve

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

FHI 360

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Medical Research Council, South Africa

OTHER

collaborator

University of Cape Town

OTHER

collaborator

University of Limpopo

OTHER

collaborator

United States Agency for International Development (USAID)

FED

lead

Population Council

OTHER

NCT00213018 - Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission | Biotech Hunter | Biotech Hunter